11 12 13 14 15 16 17 18 19 PASP and BNP/NT-­‐proBNP 2 2 Summary 1 Our objective was to evaluate the utility of the natriuretic peptides BNP (brain natriuretic 2 peptide) and NT-proBNP as markers of pulmonary artery systolic pressure (PASP) in trekkers 3 ascending to high altitude (HA). 20 participants had BNP and NT-proBNP assayed and 4 simultaneous echocardiographic assessment of PASP performe...

BACKGROUND Increases in plasma B-type natriuretic peptide (BNP) concentrations in those with acutely decompensated heart failure (ADHF) has been mainly attributed to an increase in NPPB gene transcription. Recently, proBNP glycosylation has emerged as a potential regulatory mechanism in the production of amino-terminal (NT)-proBNP and BNP. The aim of the present study was to investigate proBNP ...

The measurements of B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), when taken together with conventional clinical assessment, may assist in making the prognosis and also for making serial adjustment of such treatment. But although such commercial assays are currently approved for the diagnosis of heart failure, the role of the natriuretic peptides for monitoring the success ...

BACKGROUND Natriuretic peptides are recognized as important predictors of cardiovascular events in patients with heart failure, but less is known about their prognostic importance in patients with acute coronary syndrome. We sought to determine whether B-type natriuretic peptide (BNP) and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) could enhance risk prediction of a broad range...

INTRODUCTION Brain natriuretic peptide (BNP) levels correlate with functional capacity in patients with heart failure. Autonomic dysfunction and baro-chemo reflex balance play a role in conditioning exercise tolerance and chronotropic competence in heart failure. In this study we examined the relationship between N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and heart rate (HR) response...

PURPOSE NT-proBNP and BNP concentrations in CHF correlate with NYHA class and LVEE Little research has been conducted to compare the clinical performance of these two natriuretic peptides in heterogeneous CHF population. Purpose: to evaluate and compare the clinical performance of NT-proBNP and BNP in heterogeneous group of CHF patients on the basis of these peptides' correlation with NYHA clas...

BACKGROUND Concomitant occurrence of kidney disease (KD) and heart failure (HF) is common and associated with poor outcomes. Natriuretic peptide studies have typically excluded many individuals with KD. We compared the accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) for diagnosing decompensated HF and predicting mortality across the spectrum of renal function. M...

B-type natriuretic peptide (BNP) is a member of a fournatriuretic peptide family that shares a common 17-peptide ring structure. The N-terminal fragment (NT-pro-BNP) is biologically inert, but both are secreted in the plasma in equimolar quantities and both have been evaluated for use in the management of congestive heart failure. BNP and NT-pro-BNP are frequently used in the diagnosis of conge...

INTRODUCTION Natriuretic peptides are secreted from the heart in response to increased wall stress. Their levels are expected to be increased in patients with mitral stenosis (MS) due to high left atrium (LA) pressure and pulmonary artery pressure (PAP). Percutaneous transvenous mitral commissurotomy (PTMC) if successful is pursued by a rapid decrease in LA pressure and subsequent decrease in p...

BACKGROUND Renal dysfunction is considered a confounding variable in the interpretation of B-type natriuretic peptides (BNPs) and their amino-terminal fragments (NT-ProBNP) in patients with heart failure (HF). Our aim was to investigate the prognostic utility of BNPs and NT-proBNP in HF outpatients with renal dysfunction, and compare the prognostic significance of the corresponding BNP/NT-ProBN...